New insights in the follow-up of differentiated thyroid carcinoma

Dit document is (ook) beschikbaar voor ruilverkeer - alleen door bibliotheken -. [Bestelformulier]

Generally, differentiated thyroid cancer (DTC), including papillary and dollicular thyroid cancer, carries an excellent prognosis. Ten-year survival rates range between 83% and 98%. This favorable prognosis results from both the effective initial therapy and the generally indolent biological behavior of this tumor. Initial therapy consists of total thyroidectomy followed by high dose radioiodine therapy to eliminate microscopic residual or metastatic disease and subsequent lifelong thyroid hormone suppletion therapy. Despite the favorable general prognosis, recurrence rates are high, as up to 20% develop recurrent disease during follow-up. Recurences may become clinically evident even after 20 years following this initial therapy. Therefore lifelong follow-up of thyroid cancer patients is recommended. Follow-up strategies should be able to identify patients with recurrent disease. However, a proper balance between the diagnostic yield of monitoring tests and the associated patient burden and medical costs should be maintained.

Meer informatie in de catalogus
Meer informatie in Picarta